Lazertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Phase II Multicenter Trial
Lazertinib reported promising efficacy and a manageable safety profile in patients with NSCLC with uncommon EGFR mutations, particularly for G719X, S768I, and L861Q subtypes. These results suggest lazertinib could be an effective treatment option for this heterogeneous patient population with limited therapeutic alternatives.
Authors
- Min Hee Hong (ORCID: https://orcid.org/0000-0003-3490-2195)
- Myung‐Ju Ahn (ORCID: https://orcid.org/0000-0002-5376-5109)
- Jii Bum Lee (ORCID: https://orcid.org/0000-0001-5608-3157)
- Hye Ryun Kim (ORCID: https://orcid.org/0000-0002-1842-9070)
- Jinyong Kim
- S.Y. Lee (ORCID: https://orcid.org/0000-0001-9467-8856)
- Byoung Chul Cho (ORCID: https://orcid.org/0000-0002-5562-270X)
- Hee Kyung Ahn (ORCID: https://orcid.org/0000-0001-7786-7233)
- Sehhoon Park (ORCID: https://orcid.org/0000-0001-9467-461X)
- Sun Min Lim (ORCID: https://orcid.org/0000-0001-5956-6920)
- Hyun Ae Jung
- Jin Seok Ahn
- Young Joo Min
- Se-Hoon Lee
- Jong-Mu Sun
Institutions
- Ulsan College (KR)
- Yonsei University (KR)
- Severance Hospital (KR)
- Samsung Medical Center (KR)
- University of Ulsan (KR)
- Gachon University Gil Medical Center (KR)
- Ulsan University Hospital (KR)
- Gangnam Severance Hospital (KR)
- Yonsei University Health System (KR)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- Journal of Thoracic Oncology
- Published
- 2025-05-09
- DOI
- https://doi.org/10.1016/j.jtho.2025.05.006
- Citations
- 3
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 4.56